6-氟-(9ci)-1H-吲哚-5-醇 | 288386-15-2

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吲哚及其衍生物
• 中文名称: 6-氟-(9ci)-1H-吲哚-5-醇
• 中文别名: 6-氟-5-羟基吲哚；6-氟-(9CI)-1H-吲哚-5-醇
• 英文名称: 6-fluoro-5-hydroxyindole
• 英文别名: 6-fluoro-1H-indol-5-ol
• CAS: 288386-15-2
• 化学式: C₈H₆FNO
• mdl: MFCD09879886
• 分子量: 151.14
• InChiKey: XQJHCCZRXUOIGW-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.8
• 重原子数：
  11
• 可旋转键数：
  0
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  36
• 氢给体数：
  2
• 氢受体数：
  2

安全信息

• 储存条件：
  室温且干燥

反应信息

• 作为反应物：
  描述：

  6-氟-(9ci)-1H-吲哚-5-醇 在 caesium carbonate 作用下， 以 二甲基亚砜 为溶剂， 生成 4-Amino-6-(6-fluoro-1H-indol-5-yloxy)-pyrimidine-5-carbaldehyde O-methyl-oxime
  参考文献：
  名称：

  Synthesis and biological study of 4-aminopyrimidine-5-carboxaldehyde oximes as antiproliferative VEGFR-2 inhibitors

  摘要：

  A novel 4-aminopyrimidine-5-carboxaldehyde oxime scaffold with inhibitory activity against VEGFR-2 kinase has been identified. With a 4-fluoro-2-methylindol-5-yloxy group at the 6-position and alkyl groups as the oxime side chains, many analogues showed good potency for VEGFR-2. This series also exhibited antiproliferative activity against cancer cells, causing cell accumulation at the G2/M phase of the cell cycle and preventing cells from entering mitosis. Described here are the chemistry, structure-activity relationships (SAR), and biological testing for this series.

  DOI：

  10.1016/j.bmcl.2006.08.107
• 作为产物：
  描述：

  3-Benzyloxy-2-fluoro-6-nitrophenylacetonitrile 、 2-(5-(Benzyloxy)-4-fluoro-2-nitrophenyl)acetonitrile 、 氢气 在 钯 methylene chloride petroleum ether 作用下， 以 乙醇 、 溶剂黄146 为溶剂， 以to give 4-fluoro-5-hydroxyindole (2.48 g) and 6-fluoro-5-hydroxyindole (3.5 g)的产率得到4-氟-5-羟基吲哚
  参考文献：
  名称：

  Chemical compounds

  摘要：

  本发明涉及式(I)的化合物： 其中：环C是9或10元素的双环杂芳基团，该团至少含有一个连接到Z的环中氮原子，并且可以选择性地包含另外1-3个杂原子，独立选自O，S和N，但须注意环C不是喹唑啉，喹啉或茜啉基团；G1、G2、G3、G4和G5中的任意一个是氮，其余四个是-CH-；或G1、G2、G3、G4和G5均为-CH-；Z是-O-、NH-、-S-、CH2-或直接取代基，R1可以连接到吲哚、氮杂吲哚或吲唑基团的任何自由碳原子；m为0到2的整数；Rb代表氢或定义如下的另一个值；R1代表氢、羟基、卤素、C1-4烷基或定义如下的任何其他值；R2代表氢、羟基、卤素、氰基、硝基、三氟甲基、C1-3烷基、C1-3烷氧基、C1-3烷基硫醇基、-NR3R4（其中R3和R4，可以是相同的或不同的，每个代表氢或C1-3烷基），或R5X1-（其中R5和X1如定义）及其盐，制备这种化合物的方法，以及制备的药物组成物。

  公开号：

  US20030207878A1

文献信息

• APOPTOSIS-INDUCING AGENTS FOR THE TREATMENT OF CANCER AND IMMUNE AND AUTOIMMUNE DISEASES
  申请人：Kunzer Aaron R.

  公开号：US20100184766A1

  公开（公告）日：2010-07-22

  Disclosed are compounds which inhibit the activity of anti-apoptotic Bcl-2 proteins, compositions containing the compounds and methods of treating diseases during which is expressed anti-apoptotic Bcl-2 protein.

  公开了抑制抗凋亡Bcl-2蛋白活性的化合物，包含这些化合物的组合物以及治疗表达抗凋亡Bcl-2蛋白疾病的方法。
• Quinoline derivatives having vegf inhibiting activity
  申请人：——

  公开号：US20030199491A1

  公开（公告）日：2003-10-23

  The invention relates to compounds of formula (I) wherein: either any one of G 1 , G 2 , G 3 , G 4 and G 5 is nitrogen and the other four are —CH—, or G 1 , G 2 , G 3 , G 4 and G 5 are all —CH—; Z is —O—, —NH—, —S—, —CH 2 — or a direct bond; Z is linked to any one of G 1 , G 2 , G 3 and G 4 ; n is an integer from 0 to 5; m is an integer from 0 to 3; R a represents hydrogen or fluoro; R b , R 1 and R 2 are defined herein and salt thereof, process for the preparation so such compounds, pharmaceutical compositions containing a compound of formula I or a pharmaceutically acceptable salt thereof as active ingredient and the use of a compound of formula I in the manufacture of a medicament for the production of an antiangiogenic and/or vascular permeability reducing effect in warm-blodded animals. The compounds of formula I and the pharmaceutically acceptable salts thereof inhibit the effects of VEGF, a property of value in the treatment of a number of diseases states including cancer and rheumatoid arthritis.

  该发明涉及以下式（I）的化合物：其中：G1、G2、G3、G4和G5中的任意一个是氮，其他四个是—CH—，或者G1、G2、G3、G4和G5都是—CH—；Z是—O—、—NH—、—S—、—CH2—或直接键；Z与G1、G2、G3和G4中的任意一个相连；n是从0到5的整数；m是从0到3的整数；R代表氢或氟；Rb、R1和R2在此处定义，并且其盐，制备这种化合物的方法，含有式I的化合物或其药学上可接受的盐作为活性成分的药物组合物，以及利用式I的化合物制造用于在温血动物中产生抗血管生成和/或血管通透性降低作用的药物的用途。式I的化合物及其药学上可接受的盐抑制VEGF的作用，这是治疗多种疾病状态的有价值的特性，包括癌症和类风湿性关节炎。
• [EN] VEGFR TYROSINE KINASE INHIBITORS<br/>[FR] INHIBITEURS DE TYROSINE KINASE VEGFR
  申请人：SUZHOU VIVOTIDE BIOTECHNOLOGIES CO LTD

  公开号：WO2014183300A1

  公开（公告）日：2014-11-20

  Novel compounds, their prodrugs, and the pharmaceutically acceptable salts as pharmaceutical compositions containing such compounds useful in treating certain diseases modulated by the inhibition of vascular endothelial growth factors (VEGFs) receptor tyrosine kinases are provided. In particular, compounds and compositions and the methods for the prophylaxis, management and treatment of cancers through the inhibition of VEGF receptor tyrosine kinases are provided.

  提供了作为含有这些化合物的药物组合物的前药和药用盐，用于治疗受血管内皮生长因子（VEGFs）受体酪氨酸激酶抑制调节的特定疾病。具体提供了通过抑制VEGF受体酪氨酸激酶来预防、管理和治疗癌症的化合物、组合物和方法。
• Synthesis of redox-active fluorinated 5-hydroxytryptophans as molecular reporters for biological electron transfer
  作者：Amanda Ohler、Hanna Long、Kei Ohgo、Kristin Tyson、David Murray、Amanda Davis、Chris Whittington、Eli G. Hvastkovs、Liam Duffy、Alice Haddy、Andrew L. Sargent、William E. Allen、Adam R. Offenbacher

  DOI：10.1039/d1cc00187f

  日期：——

  Chemoenzymatic synthesis of fluorinated 5-hydroxytryptophans provides a novel set of non-canonical tryptophan amino acids useful for probes of biological electron transfer reactions.

  通过化酶合成氟化5-羟基色氨酸，提供了一组新型的非规范色氨酸氨基酸，可用于生物电子转移反应的探针。
• [EN] QUINAZOLINE DERIVATIVES AS ANGIOGENESIS INHIBITORS<br/>[FR] DERIVES DE QUINAZOLINE UTILISES COMME INHIBITEURS DE L'ANGIOGENESE
  申请人：ASTRAZENECA UK LTD

  公开号：WO2000047212A1

  公开（公告）日：2000-08-17

  The invention relates to the use of compounds of formula (I), wherein ring C is an 8, 9, 10, 12 or 13-membered bicyclic or tricyclic moiety which optionally may contain 1-3 heteroatoms selected independently from O, N and S; Z is -O-, -NH-, -S-, -CH2- or a direct bond; n is 0-5; m is 0-3; R2 represents hydrogen, hydroxy, halogeno, cyano, nitro, trifluoromethyl, C¿1-3?alkyl, C1-3alkoxy, C1-3alkylsulphanyl, -NR?3R4¿ (wherein R?3 and R4¿, which may be the same or different, each represents hydrogen or C¿1-3?alkyl), or R?5X1¿- (wherein X?1 and R5¿ are as defined herein; R1 represents hydrogen, oxo, halogeno, hydroxy, C¿1-4?alkoxy, C1-4alkyl, C1-4alkoxymethyl, C1-4alkanoyl, C1-4haloalkyl, cyano, amino, C2-5alkenyl, C2-5alkynyl, C1-3alkanoyloxy, nitro, C1-4alkanoylamino, C1-4alkoxycarbonyl, C1-4alkylsulphanyl, C1-4alkylsulphinyl, C1-4alkylsulphonyl, carbamoyl, N-C1-4alkylcarbamoyl, N,N-di(C1-4alkyl)carbamoyl, aminosulphonyl, N-C1-4alkylaminosulphonyl, N,N-di(C1-4alkyl)aminosulphonyl, N-(C1-4alkylsulphonyl)amino, N-(C1-4alkylsulphonyl)-N-(C1-4alkyl)amino, N,N-di(C1-4alkylsulphonyl)amino, a C3-7alkylene chain joined to two ring C carbon atoms, C1-4alkanoylaminoC1-4alkyl, carboxy or a group R?56X10¿ (wherein X?10 and R56¿ are as defined herein); and salts thereof, in the manufacture of a medicament for use in the production of an antiangiogenic and/or vascular permeability reducing effect in warm-blooded animals, processes for the preparation of such compounds, pharmaceutical compositions containing a compound of formula (I) or a pharmaceutically acceptable salt thereof as active ingredient and compounds of formula (I). The compounds of formula (I) and the pharmaceutically acceptable salts thereof inhibit the effects of VEGF, a property of value in the treatment of a number of disease states including cancer and rheumatoid arthritis.

  本发明涉及使用式(I)的化合物，其中环C是一个含有1-3个杂原子（独立选择自O、N和S）的8、9、10、12或13元的双环或三环基团；Z是-O-、-NH-、-S-、-CH2-或直接键；n为0-5；m为0-3；R2代表氢、羟基、卤代、氰基、硝基、三氟甲基、C1-3烷基、C1-3烷氧基、C1-3烷基硫基、-NR3R4（其中R3和R4，可能相同或不同，每个代表氢或C1-3烷基），或R5X1-（其中X1和R5如上定义）；R1代表氢、氧代、卤代、羟基、C1-4烷氧基、C1-4烷基、C1-4烷氧甲基、C1-4烷酰基、C1-4卤代烷基、氰基、氨基、C2-5烯基、C2-5炔基、C1-3烷酰氧基、硝基、C1-4烷酰胺基、C1-4烷氧羰基、C1-4烷基硫基、C1-4烷基亚砜基、C1-4烷基磺酰基、氨基甲酰基、N-C1-4烷基氨基甲酰基、N,N-二(C1-4烷基)氨基甲酰基、氨基磺酰基、N-C1-4烷基氨基磺酰基、N,N-二(C1-4烷基)氨基磺酰基、N-(C1-4烷基磺酰基)氨基、N-(C1-4烷基磺酰基)-N-(C1-4烷基)氨基、N,N-二(C1-4烷基磺酰基)氨基、与两个环C碳原子连接的C3-7烷基链、C1-4烷酰胺基C1-4烷基、羧基或R56X10基团（其中X10和R56如上定义）；以及其盐，在制备用于在温血动物中产生抗血管生成和/或血管通透性降低效应的药物中使用，制备这种化合物的过程，包含式(I)的化合物或其药学上可接受的盐作为活性成分的制药组合物和式(I)的化合物。式(I)的化合物及其药学上可接受的盐抑制VEGF的效果，这是治疗包括癌症和类风湿性关节炎在内的许多疾病状态的有价值的属性。